BioCentury
ARTICLE | Clinical News

Cara gains after analgesic readout

June 27, 2018 8:24 PM UTC

Cara Therapeutics Inc. (NASDAQ:CARA) added $1.62 (10%) to $18.06 Wednesday after IV CR845 met the primary and secondary endpoints in the adaptive Phase II/III CLIN3001 study to treat postoperative pain in patients undergoing abdominal surgery.

On the primary endpoint, the 1 µg/kg dose of IV CR845 significantly improved pain relief as measured by area under the curve (AUC) of the Numerical Rating Scale (NRS) over 24 hours postsurgery vs. placebo (p=0.032). A 0.5 µg/kg dose missed the primary endpoint vs. placebo (p=0.076)...

BCIQ Company Profiles

Cara Therapeutics Inc.